Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance

Amneal Pharmaceuticals stock has delivered a very strong 345.7% return over the past 3 years, yet its valuation checks lean more on the expensive side rather than flagging it as a clear bargain.

• Over the last 3 years Amneal Pharmaceuticals has returned 345.7%, which puts extra focus on whether the current share price already reflects much of the good news.
• Recent earnings strength and higher expectations for future revenue and profit can support the current valuation, but any disappointment in execution or demand trends may weigh heavily on the stock after such a strong run.
• Amneal Pharmaceuticals passes only 2 out of 6 valuation checks, which suggests it does not screen as obviously cheap on broader measures.

The issue now is whether Amneal Pharmaceuticals shares are already pricing in most of the good news or if there is still room for further upside without stretching valuation too far.

Amneal Pharmaceuticals delivered 134.0% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Where Does Amneal Pharmaceuticals Sit on Earnings?

The P/E ratio fits Amneal Pharmaceuticals well because earnings are a key focus for investors after its recent profit strength. Right now the stock trades on about 37.1x earnings, which is well above the Pharmaceuticals industry average of roughly 15.4x and also higher than the peer group average of about 20.4x. That kind of premium suggests the market already places a higher value on each dollar of Amneal Pharmaceuticals earnings than it does for many competitors.

The Fair P/E Ratio, which blends factors like the company’s growth profile, margins, market size and risk, sits at about 34.1x. That is only slightly below the current 37.1x multiple, so the gap is not extreme. Despite the strong Q2 2026 results and higher full year guidance, the current price looks broadly in line with what this framework suggests investors might pay for Amneal Pharmaceuticals earnings.

Overall, Amneal Pharmaceuticals stock appears to be priced roughly fairly on its P/E multiple, with only a modest premium to the model’s fair level.

See what the numbers say about this price — find out in our valuation breakdown.

The Amneal Pharmaceuticals Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives pick up where the valuation questions around Amneal Pharmaceuticals leave off and spell out what would need to happen with Amneal Pharmaceuticals’ growth, margins and earnings for the stock to be worth materially more or less than today. Each narrative treats fair value as a thesis about how the business might develop that you can later compare against what actually occurs, and they sit on Simply Wall St’s Community page.

The community is split on Amneal Pharmaceuticals, with one camp seeing meaningful upside and the other arguing expectations are already stretched.

Bull case: 20% undervalued

“Management describes the current period as a golden era for biosimilars, with a large wave of biologic loss of exclusivity and an estimated global biosimilars market expansion toward US$200b by 2035…”

Read the full Bull Case to see why Amneal Pharmaceuticals could be undervalued

Bear case: 15% overvalued

“Reliance on a large and growing biosimilars pipeline, including more than 20 programs and capacity expansion from approximately 26,000 liters to 75,000 liters by 2028, could expose Amneal Pharmaceuticals to execution setbacks, regulatory delays and slower than expected customer adoption…”

Read the full Bear Case to see why Amneal Pharmaceuticals could be overvalued

Do you think there’s more to the story for Amneal Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

For Amneal Pharmaceuticals, the current P/E premium suggests the stock is priced about right rather than clearly cheap or clearly expensive. The key question is whether earnings and margins can develop strongly enough to keep justifying that premium without leaving little room for error. After such a large move in the share price, expectations are already high, so any slip in execution, biosimilar uptake or demand trends could matter more than usual. The crux of the bull versus bear debate is whether recent earnings strength proves durable enough to support today’s valuation over time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com